Stephen Aselage's Insider Trades & SAST Disclosures
Stephen Aselage's most recent trade in Biocryst Pharmaceuticals Inc. was a trade of 49,933 Automatic Stock Option Grant done . Disclosure was reported to the exchange on June 12, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Stephen Aselage.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biocryst Pharmaceuticals Inc. | Stephen J. Aselage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 49,933 | 49,933 | - | - | Automatic Stock Option Grant | |
| Biocryst Pharmaceuticals Inc. | Stephen J. Aselage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 6,820 | 70,159 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharmaceuticals Inc. | Stephen J. Aselage | Director | Purchase of securities on an exchange or from another person at price $ 6.40 per share. | 24 May 2024 | 2,500 | 2,500 (0%) | 0% | 6.4 | 16,000 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Stephen J. Aselage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 39,072 | 39,072 | - | - | Automatic Stock Option Grant | |
| Biocryst Pharmaceuticals Inc. | Stephen J. Aselage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 16,745 | 63,339 (0%) | 0% | 0 | Common Stock | |
| Acer Therapeutics Inc | Stephen Aselage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2023 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Acer Therapeutics Inc | Stephen Aselage | Director | Purchase of securities on an exchange or from another person at price $ 1.22 per share. | 29 Nov 2022 | 409,836 | 483,741 (4%) | 4% | 1.2 | 500,000 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Stephen J. Aselage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 30,022 | 30,022 | - | - | Automatic Stock Option Grant | |
| Biocryst Pharmaceuticals Inc. | Stephen J. Aselage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 12,866 | 46,594 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharmaceuticals Inc. | Stephen J. Aselage | Director | Grant, award, or other acquisition of securities at price $ 9.31 per share. | 31 May 2022 | 569 | 33,728 (0%) | 0% | 9.3 | 5,297 | Common Stock |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Sale of securities on an exchange or to another person at price $ 21.93 per share. | 11 May 2022 | 2,575 | 146,919 (0%) | 0% | 21.9 | 56,457 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Stephen J. Aselage | Director | Grant, award, or other acquisition of securities at price $ 16.61 per share. | 28 Feb 2022 | 301 | 33,159 (0%) | 0% | 16.6 | 5,000 | Common Stock |
| Acer Therapeutics Inc | Stephen Aselage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 18,500 | 18,500 | - | - | Stock Option (right to buy) | |
| Acer Therapeutics Inc | Stephen Aselage | Director | Purchase of securities on an exchange or from another person at price $ 2.04 per share. | 09 Dec 2021 | 7,984 | 73,905 (0%) | 0% | 2.0 | 16,287 | Common Stock |
| Acer Therapeutics Inc | Stephen Aselage | Director | Purchase of securities on an exchange or from another person at price $ 2.15 per share. | 09 Dec 2021 | 2,016 | 65,921 (0%) | 0% | 2.1 | 4,334 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Stephen J. Aselage | Director | Grant, award, or other acquisition of securities at price $ 12.06 per share. | 30 Nov 2021 | 414 | 32,858 (0%) | 0% | 12.1 | 4,993 | Common Stock |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Sale of securities on an exchange or to another person at price $ 29.39 per share. | 16 Nov 2021 | 31,800 | 149,494 (0%) | 0% | 29.4 | 934,602 | Common Stock |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2021 | 10,000 | 70,000 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Sale of securities on an exchange or to another person at price $ 26.23 per share. | 05 Nov 2021 | 10,000 | 161,794 (0%) | 0% | 26.2 | 262,300 | Common Stock |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.23 per share. | 05 Nov 2021 | 10,000 | 171,794 (0%) | 0% | 16.2 | 162,300 | Common Stock |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 01 Nov 2021 | 25,000 | 164,794 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 01 Nov 2021 | 25,000 | 25,000 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Sale of securities on an exchange or to another person at price $ 29.48 per share. | 01 Nov 2021 | 5,000 | 23,000 (0%) | 0% | 29.5 | 147,400 | Common Stock |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 01 Nov 2021 | 3,500 | 19,500 (0%) | 0% | 30 | 105,000 | Common Stock |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 01 Nov 2021 | 3,000 | 28,000 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 01 Nov 2021 | 3,000 | 161,794 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.23 per share. | 07 Oct 2021 | 60,000 | 249,794 (0%) | 0% | 16.2 | 973,800 | Common Stock |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Oct 2021 | 60,000 | 80,000 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Sale of securities on an exchange or to another person at price $ 26.26 per share. | 07 Oct 2021 | 32,000 | 189,794 (0%) | 0% | 26.3 | 840,320 | Common Stock |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Sale of securities on an exchange or to another person at price $ 26.23 per share. | 07 Oct 2021 | 28,000 | 221,794 (0%) | 0% | 26.2 | 734,440 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Stephen J. Aselage | Director | Grant, award, or other acquisition of securities at price $ 15.92 per share. | 31 Aug 2021 | 314 | 32,444 (0%) | 0% | 15.9 | 4,999 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Stephen J. Aselage | Director | Grant, award, or other acquisition of securities at price $ 15.77 per share. | 28 May 2021 | 634 | 32,130 (0%) | 0% | 15.8 | 9,998 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Stephen J. Aselage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2021 | 40,000 | 40,000 | - | - | Automatic Stock Option Grant | |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 9,000 | 9,000 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 3,000 | 189,794 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Sale of securities on an exchange or to another person at price $ 19.58 per share. | 11 May 2021 | 2,146 | 186,794 (0%) | 0% | 19.6 | 42,023 | Common Stock |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Sale of securities on an exchange or to another person at price $ 26.23 per share. | 16 Apr 2021 | 10,000 | 188,940 (0%) | 0% | 26.2 | 262,300 | Common Stock |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.23 per share. | 16 Apr 2021 | 10,000 | 198,940 (0%) | 0% | 16.2 | 162,300 | Common Stock |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2021 | 10,000 | 140,000 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Mar 2021 | 10,000 | 150,000 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Sale of securities on an exchange or to another person at price $ 27.35 per share. | 17 Mar 2021 | 10,000 | 196,667 (0%) | 0% | 27.4 | 273,500 | Common Stock |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.23 per share. | 17 Mar 2021 | 10,000 | 206,667 (0%) | 0% | 16.2 | 162,300 | Common Stock |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Sale of securities on an exchange or to another person at price $ 27.56 per share. | 17 Mar 2021 | 7,727 | 188,940 (0%) | 0% | 27.6 | 212,956 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Stephen J. Aselage | Director | Grant, award, or other acquisition of securities at price $ 10.78 per share. | 26 Feb 2021 | 927 | 31,496 (0%) | 0% | 10.8 | 9,993 | Common Stock |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Sale of securities on an exchange or to another person at price $ 30.75 per share. | 02 Feb 2021 | 25,000 | 196,667 (0%) | 0% | 30.8 | 768,750 | Common Stock |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.09 per share. | 02 Feb 2021 | 25,000 | 221,667 (0%) | 0% | 10.1 | 252,250 | Common Stock |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2021 | 25,000 | 275,000 | - | - | Employee stock option (right to buy) | |
| Acer Therapeutics Inc | Stephen Aselage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Travere Therapeutics Inc | Stephen Aselage | Director | Sale of securities on an exchange or to another person at price $ 26.02 per share. | 15 Dec 2020 | 5,549 | 196,667 (0%) | 0% | 26.0 | 144,385 | Common Stock |
| Travere Therapeutics Inc | Stephen Aselage | Director | Sale of securities on an exchange or to another person at price $ 23.43 per share. | 02 Dec 2020 | 7,891 | 202,216 (0%) | 0% | 23.4 | 184,849 | Common Stock |
| Travere Therapeutics Inc | Stephen Aselage | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 02 Dec 2020 | 3,000 | 210,107 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharmaceuticals Inc. | Stephen Aselage | Director | Grant, award, or other acquisition of securities at price $ 5.11 per share. | 30 Nov 2020 | 1,956 | 30,569 (0%) | 0% | 5.1 | 9,995 | Common Stock |
| Travere Therapeutics Inc | Stephen Aselage | Director | Sale of securities on an exchange or to another person at price $ 23.00 per share. | 05 Nov 2020 | 20,625 | 213,107 (0%) | 0% | 23 | 474,375 | Common Stock |
| Travere Therapeutics Inc | Stephen Aselage | Director | Sale of securities on an exchange or to another person at price $ 21.26 per share. | 05 Nov 2020 | 2,500 | 233,732 (0%) | 0% | 21.3 | 53,150 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Stephen Aselage | Director | Grant, award, or other acquisition of securities at price $ 4.15 per share. | 31 Aug 2020 | 2,409 | 28,613 (0%) | 0% | 4.1 | 9,997 | Common Stock |
| Travere Therapeutics Inc | Stephen Aselage | Director | Sale of securities on an exchange or to another person at price $ 19.68 per share. | 05 Aug 2020 | 2,500 | 236,232 (0%) | 0% | 19.7 | 49,200 | Common Stock |
| Acer Therapeutics Inc | Stephen Aselage | None | Purchase of securities on an exchange or from another person at price $ 3.50 per share. | 24 Jul 2020 | 45,000 | 63,905 (0%) | 0% | 3.5 | 157,500 | Common Stock |
| Travere Therapeutics Inc | Stephen Aselage | Director | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 25 Jun 2020 | 10,000 | 238,732 (0%) | 0% | 20 | 200,000 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges